Suppr超能文献

重症监护病房中接受异基因造血干细胞移植的危重症患者:实际预后的重新评估

Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis.

作者信息

Saillard C, Blaise D, Mokart D

机构信息

Department of Hematology, Institut Paoli Calmettes, Marseille, France.

Polyvalent Intensive Care Unit, Department of Anesthesiology and Critical Care, Institut Paoli Calmettes, Marseille, France.

出版信息

Bone Marrow Transplant. 2016 Aug;51(8):1050-61. doi: 10.1038/bmt.2016.72. Epub 2016 Apr 4.

Abstract

The outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients has significantly improved over the past decade. Still, a significant number of patients require intensive care unit (ICU) management because of life-threatening complications. Literature from the 1990s reported extremely poor prognosis for critically ill allo-HSCT patients requiring ICU management. Recent data justify the use of ICU resources in hematologic patients. Yet, allo-HSCT remains an independent variable associated with mortality. However, outcomes in allo-HSCT patients have improved over time and many classic determinants of mortality have become irrelevant. The main actual prognostic factors are the need for mechanical ventilation, the presence of GvHD and the number of organ failures at ICU admission. Recently, the development of reduced-intensity conditioning regimens, early ICU admission and the increased use of noninvasive ventilation, combined with time effect and general advances in hematology, in allo-HSCT procedures and in ICU management have contributed to improve general outcome. A rational policy of ICU admission triage in these patients is very hard to define, as each decision for ICU admission is a case-by-case decision at patient bedside. The collaboration between hematologists and intensivists is crucial in this context.

摘要

在过去十年中,异基因造血干细胞移植(allo-HSCT)患者的预后有了显著改善。然而,仍有相当数量的患者因危及生命的并发症而需要重症监护病房(ICU)管理。20世纪90年代的文献报道,需要ICU管理的重症allo-HSCT患者预后极差。最近的数据证明了在血液学患者中使用ICU资源的合理性。然而,allo-HSCT仍然是一个与死亡率相关的独立变量。不过,随着时间的推移,allo-HSCT患者的预后有所改善,许多经典的死亡决定因素已不再相关。目前主要的预后因素是是否需要机械通气、是否存在移植物抗宿主病(GvHD)以及入住ICU时器官衰竭的数量。最近,减低强度预处理方案的发展、早期入住ICU以及无创通气使用的增加,再加上时间效应以及血液学、allo-HSCT程序和ICU管理方面的总体进展,都有助于改善总体预后。很难为这些患者制定一个合理的ICU入住分诊政策,因为每次关于ICU入住的决定都是在患者床边根据具体情况做出的。在这种情况下,血液科医生和重症监护医生之间的合作至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验